Plain-English translation of NCT06053658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This Phase 2 trial is testing a combination of two medications— and —to see if they work well together against advanced non-clear cell renal cell carcinoma, a type of kidney cancer. Researchers want to learn whether this medication combination can shrink tumors and help patients live longer. This study will include about 48 patients.
Non-clear cell kidney cancers are harder to treat than the more common clear cell type, and current treatment options don't work well for everyone. This trial explores whether pairing a targeted drug with an immunotherapy drug might be more effective than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would take tablets by mouth every day for 21 days of each 28-day cycle, then skip 7 days. Every 4 weeks you would also receive as an intravenous infusion over about 60 minutes. You would have regular clinic visits, blood tests, and imaging scans to check how the cancer is responding and monitor for side effects. The trial involves up to 48 patients total and will track how long the treatment keeps your cancer under control.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States